Can a simple blood test spot lymphoma earlier?

NCT ID NCT07750886

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study gathers blood and leftover tissue samples from 200 people newly diagnosed with aggressive non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and T-cell lymphoma. The samples are used to develop and validate blood-based tests that could monitor cancer and detect its return. Participants provide up to 60 mL of blood and allow use of tissue from standard procedures. The goal is to improve how lymphoma is tracked and managed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Blood and residual tissue sample collection for research (no drug or device)
What this could lead to
If successful, this could lead to better blood tests for monitoring and detecting non-Hodgkin lymphoma, potentially improving how the disease is tracked and managed.
What could go wrong
This is an early-stage sample collection study, not a treatment trial. The tests developed may not prove accurate or useful in clinical practice, and results are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Natera, Inc.

    RECRUITING

    Austin, Texas, 78753, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.